Safety and Tolerability of Antibody-Drug Conjugates in Cancer

Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting

(2018) Auayporn Nademanee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE

(2018) Elias J. Jabbour et al.   CANCER

A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

(2018) Marek Trněný et al.   HAEMATOLOGICA

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients

(2018) Tiina Moilanen et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

(2018) Tomomi Nakayama Iwata et al.   MOLECULAR CANCER THERAPEUTICS

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

(2018) Marek Trněný et al.   HAEMATOLOGICA

Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia

(2018) Jennifer Hibma et al.   CLINICAL PHARMACOKINETICS

Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.

(2018) Hiroji Iwata et al.   JOURNAL OF CLINICAL ONCOLOGY

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption

(2017) Francis S. Wolenski et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

(2017) H Miles Prince et al.   LANCET

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

(2017) Véronique Diéras et al.   LANCET ONCOLOGY

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

(2017) Hagop M Kantarjian et al.   Lancet Haematology

Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review

(2017) Michael D. DeVita et al.   Journal of the National Comprehensive Cancer Network

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment

(2016) Baiteng Zhao et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

(2016) Bertrand Coiffier et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

(2016) Jamie E. Flerlage et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma

(2016) Eunhye Oak et al.   Expert Opinion On Drug Safety

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1)vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer

(2016) Sung-Bae Kim et al.   INTERNATIONAL JOURNAL OF CANCER

Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine

(2016) Jeremy Force et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

(2016) Sergio Amadori et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: a Meta-analysis

(2016) Kai Shen et al.   Scientific Reports

Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates

(2015) Samantha Gromek et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Targeting B-cell maturation antigen in multiple myeloma

(2015) Yu-Tzu Tai et al.   Immunotherapy

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

(2015) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

Current ADC Linker Chemistry

(2015) Nareshkumar Jain et al.   PHARMACEUTICAL RESEARCH

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

(2014) M. D. Gandhi et al.   BLOOD

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

(2014) Kenneth R. Carson et al.   CANCER

Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.

(2014) Johanna Bendell et al.   CANCER RESEARCH

Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature

(2014) Stefan K. Alig et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

(2014) Alan S. Gamis et al.   JOURNAL OF CLINICAL ONCOLOGY

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

(2014) Nancy L Bartlett et al.   Journal of Hematology & Oncology

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

(2014) S. Golfier et al.   MOLECULAR CANCER THERAPEUTICS

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

(2013) V. Ribrag et al.   CLINICAL CANCER RESEARCH

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2013) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

(2013) Tae H. Han et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper

(2013) Boris Gorovits et al.   Bioanalysis

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

(2011) A. D. Ricart   CLINICAL CANCER RESEARCH

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

(2010) Sergio Amadori et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE